The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as ...

The Centers for Disease Control and Prevention's vaccine advisory committee is set to meet for the first time since Health ...

We came across a bullish thesis on Moderna, Inc. (MRNA) on Natan’s Substack. In this article, we will summarize the bulls’ ...

The FDA has approved a new COVID-19 vaccine developed by Moderna, offering a lower-dose option aimed at older adults and people with underlying health risks. The vaccine, named mNexspike, is part ...

mNEXSPIKE becomes Moderna's third FDA-approved product. CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA ...

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.. The new vaccine is indicated for active immunization to prevent COVID-19 caused ...

FDA Approves Moderna’s mNEXSPIKE for High-Risk Populations: Moderna’s next-generation COVID-19 vaccine, mNEXSPIKE (mRNA-1283), has received FDA approval for adults aged 65 years and older and ...

Moderna said it plans to make mNEXSPIKE available in the U.S. for the 2025–2026 respiratory virus season, complementing its existing offerings of Spikevax and mRESVIA®, the company’s vaccine ...

The company said it expects to have the vaccine, called mNEXSPIKE, available for the 2025-2026 respiratory virus season. 4 The FDA has approved Moderna’s next-generation COVID-19 vaccine for ...

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...

mNexspike becomes Moderna’s third FDA-approved product, joining Spikevax (original COVID-19 vaccine) and mResvia (RSV vaccine). Spikevax is approved/authorized for use by the FDA in individuals ...